Skip to the main content.

Cell and Gene Therapy Series: Part 5 - Future ATMP Manufacturing Paradigms: Lessons From History

Dr. Dave Seaward : 15 March 2022

Cell and Gene Therapy Series: Part 5 - Future ATMP Manufacturing Paradigms: Lessons From History

We dive back over 100 years as we look at the history of the pharmaceutical industry to see what lessons might be learnt for ATMP production.

This blog will also look the future of ATMP paradigms, taking lessons from the past.

Click here to read.
Behind the scenes of 3P innovation's Customer Care team

Behind the scenes of 3P innovation's Customer Care team

Picture of Georgia Lewis-Marston Georgia Lewis-Marston: 17 October 2025

This week, I had the chance to sit down with Paul Beard, Operations Director at 3P innovation, to explore what truly distinguishes our Customer Care...

Read More
Filling syringes with spray-dried powders - the how, the why and the benefits.

Filling syringes with spray-dried powders - the how, the why and the benefits.

David Phasey: 15 October 2025

For many therapy developers, the challenge doesn’t start in manufacturing, it begins much earlier in formulation. Once a promising therapy has...

Read More
What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

Charles Pilato: 6 October 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More